A243 VTD Followed by MPT Demonstrates High Response Rates for High-Risk Patients with Multiple Myeloma

Autor: HS Eom, YK Kim, J Chung, K Kim, H Kim, DS Lee, J Jin, YR Do, S Oh, C Suh, CM Seong, CS Kim, JH Lee

Publikováno v: Clinical Lymphoma and Myeloma. 9:S42-S43

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::707aa32ac9a2eb780500ca2f68221004
https://doi.org/10.1016/s1557-9190(11)70520-0

Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study.

Autor: Lee JH; Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan., Choi J; Department of Management information system, College of Business Administration, Dong-A University, Busan., Min CK; Hematology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul., Park SS; Hematology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul., Jo JC; Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan., Lee YJ; Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan., Kim JS; Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul., Eom HS; Department of Hematology-Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang., Jung J; Department of Hematology-Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang., Moon JH; Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu., Cho HJ; Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu., Lee MW; Division of Hematology and Oncology,Department of Internal Medicine, Chungnam National University Hospital, Daejeon., Yoon SS; Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul., Byun JM; Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul., Lee JH; Gachon University Medical College, Division of Hematology, Gachon University Gil Medical Center, Incheon., Lee JJ; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Jeollanam-do., Jung SH; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Jeollanam-do., Shin HJ; Division of Hematology-oncology, Department of Internal Medicine, Pusan National University Hospital, Busan., Kim DY; Division of Hematology-oncology, Department of Internal Medicine, Pusan National University Hospital, Busan., Yi JH; Division of Hematology-Oncology, Department of Medicine, Chung-Ang University, Seoul., Lee SS; Department of Hematology-Oncology, Wonkwang University Hospital, Iksan., Do YR; Department of Hemato-Oncology, Keimyung University, Dongsan Medical Center, Daegu., Yoon DH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul., Cho H; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul., Lee WS; Department of Internal Medicine, Inje University Busan Paik Hospital, Busan., Lee HS; Department of Internal Medicine, Kosin University College of Medicine, Busan., Uhm J; Division of Hematology and Oncology, Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul., Kim HJ; Department of Hematology-Oncology, Hallym University Medical Center, Hallym University College of Medicine, Anyang., Jang HR; Kangwon National University Hospital, Division of Hematology, Chuncheon, Gangwon-do, South Korea; and., Kim SH; Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan. kshmoon@dau.ac.kr., Kim K; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul.

Publikováno v: Haematologica [Haematologica] 2024 Nov 01; Vol. 109 (11), pp. 3681-3692. Date of Electronic Publication: 2024 Nov 01.

Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.

Autor: Thieblemont C; Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France. catherine.thieblemont@aphp.fr., Karimi YH; Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA., Ghesquieres H; Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France., Cheah CY; Sir Charles Gairdner Hospital and the University of Western Australia, Nedlands, Australia., Clausen MR; Vejle Hospital, Vejle, Denmark., Cunningham D; The Royal Marsden NHS Foundation Trust, Sutton, UK., Jurczak W; MSC National Research Institute of Oncology, Kraków, Poland., Do YR; Keimyung University Dongsan Medical Center, Daegu, Republic of Korea., Gasiorowski R; Concord Hospital, University of Sydney, Sydney, Australia., Lewis DJ; University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, UK., Kim TM; Seoul National University Hospital, Seoul, Republic of Korea., van der Poel M; Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Maastricht, Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands., Poon ML; National University Hospital, Singapore, Singapore., Feldman T; John Theurer Cancer Center at Hackensack Meridian Health, Hackensack Meridian Health School of Medicine, Hackensack, NJ, USA., Linton KM; The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester, Manchester, UK., Sureda A; Clinical Hematology Department, Institut Català d'Oncologia - L'Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain., Hutchings M; Rigshospitalet and University of Copenhagen, Copenhagen, Denmark., Dinh MH; AbbVie, North Chicago, IL, USA., Kilavuz N; Genmab, Plainsboro, NJ, USA., Soong D; Genmab, Plainsboro, NJ, USA., Mark T; Genmab, Copenhagen, Denmark., Sacchi M; Genmab, Plainsboro, NJ, USA., Phillips T; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.; City of Hope, Duarte, CA, USA., Lugtenburg PJ; Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, Department of Hematology, University Medical Center, Rotterdam, The Netherlands.

Publikováno v: Leukemia [Leukemia] 2024 Sep 25. Date of Electronic Publication: 2024 Sep 25.

Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study.

Autor: Yhim HY; Department of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea., Park Y; Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea., Kim JA; Department of Internal Medicine, The Catholic University of Korea, St. Vincent Hospital, Suwon, Korea., Shin HJ; Department of Internal Medicine, Pusan National University Hospital, Busan, Korea., Do YR; Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea., Moon JH; Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea., Kim MK; Department of Internal Medicine, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Korea., Lee WS; Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea., Kim DS; Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea., Lee MW; Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea., Choi YS; Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea., Jeong SH; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea., Kim KH; Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea., Kim J; Department of Internal Medicine, The Catholic University of Korea, St. Vincent Hospital, Suwon, Korea., Lee CH; Department of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea., Song GY; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea., Yang DH; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea., Kwak JY; Department of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea.

Publikováno v: The Korean journal of internal medicine [Korean J Intern Med] 2024 May; Vol. 39 (3), pp. 501-512. Date of Electronic Publication: 2024 Jan 30.

Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea.

Autor: Lee JY; Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea., Kwon JH; Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea., Hur JY; Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea., Yi JH; Division of Hematology-Oncology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea., Lee JH; Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea., Cho H; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Do YR; Department of Internal Medicine, Dongsan Medical Center, Daegu, Korea., Jo JC; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea., Kang HJ; Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea., Koh Y; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea., Lee WS; Department of Internal medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea., Lim SN; Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea., Yoon SE; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Kim SJ; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Lee JO; Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

Publikováno v: Cancer research and treatment [Cancer Res Treat] 2024 Apr; Vol. 56 (2), pp. 681-687. Date of Electronic Publication: 2023 Nov 10.